STAT newsletter highlights Sen. Cassidy's loss, potential changes in health dynamics affecting Trump administration.
You're reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Would you rather get squeaky cheese curds from your MAHA senator or a fake subpoena and Tylenol from your smartalec Kennedy cousin? What I’d like is some news tips at or John_Wilkerson.07 on Signal.
Sen. Bill Cassidy’s (R-La.) primary loss is a win for MAHA, Chelsea Cirruzzo reports, but it's just one of multiple changes in dynamics that could either make life easier or more difficult for health secretary Robert F. Kennedy Jr. and the Trump administration. The addition of generic drugs to TrumpRx has been met with mixed reactions. Some view it as a strategic move to reduce costs and improve access to medications, while others see it as a potential threat to pharmaceutical companies' profits. Continue to STAT+ to read the full story about these developments and their implications for healthcare policy under the current administration.
